Atlas Trials

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Clinical trial NCT02034110 · COMPLETED

Trial details

NCT number
NCT02034110
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Cancer
Start date
2014-03-12
Primary completion
2021-12-10
Enrollment
206

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.